ProKidney Corp. (NASDAQ:PROK) Insider Control Empresarial De Capital Purchases 100,000 Shares of Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital purchased 100,000 shares of ProKidney stock in a transaction that occurred on Wednesday, April 16th. The shares were bought at an average cost of $0.75 per share, with a total value of $75,000.00. Following the completion of the transaction, the insider now directly owns 73,430,330 shares of the company’s stock, valued at approximately $55,072,747.50. The trade was a 0.14 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Control Empresarial De Capital also recently made the following trade(s):

• On Monday, April 14th, Control Empresarial De Capital purchased 268,105 shares of ProKidney stock. The stock was purchased at an average price of $0.73 per share, with a total value of $195,716.65.
• On Thursday, April 10th, Control Empresarial De Capital purchased 1,032,218 shares of ProKidney stock. The shares were acquired at an average price of $0.61 per share, with a total value of $629,652.98.

ProKidney Price Performance

PROK stock opened at $0.79 on Friday. ProKidney Corp. has a one year low of $0.46 and a one year high of $4.44. The stock has a market cap of $231.49 million, a price-to-earnings ratio of -1.44 and a beta of 1.52. The company has a fifty day moving average price of $1.03 and a two-hundred day moving average price of $1.51.

ProKidney (NASDAQ:PROK) last announced its earnings results on Monday, March 17th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.08 million during the quarter. Research analysts anticipate that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

Hedge Funds Weigh In On ProKidney

A number of hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new stake in ProKidney during the third quarter worth about $41,000. ProShare Advisors LLC boosted its position in shares of ProKidney by 57.3% during the 4th quarter. ProShare Advisors LLC now owns 30,879 shares of the company’s stock worth $52,000 after acquiring an additional 11,250 shares in the last quarter. Sei Investments Co. bought a new position in ProKidney in the fourth quarter valued at approximately $69,000. JPMorgan Chase & Co. raised its position in ProKidney by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 46,830 shares of the company’s stock valued at $90,000 after purchasing an additional 18,472 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in shares of ProKidney in the 4th quarter valued at $88,000. Institutional investors own 51.59% of the company’s stock.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.